Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stem cells (MSCs) are being investigated by The Foundation for Spinal Research, Education and Humanitarian Care, Inc. as a regenerative treatment for chronic low back pain. In a prospective cohort study (NCT02332798), the foundation compared the efficacy of autograft (patient-derived bone marrow concentrate) and allograft mesenchymal stem cell injections. The primary indications are lumbar degenerative disc disease and degenerative facet joint disease. MSCs are multipotent cells that exert therapeutic effects through paracrine signaling, releasing anti-inflammatory cytokines and growth factors that modulate the local immune environment and potentially stimulate the repair of damaged disc and facet joint tissues. The treatment involves the direct injection of these cells into the affected spinal structures to reduce pain and improve functional outcomes in patients who have failed conservative management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesenchymal stem cells (Foundation for Spinal Research).